Asan medical center
Seoul, 138-736, South Korea
NCT Number: NCT01624571
This clinical trial is conducted to determine the optimal dose of LD02GIFRO in improvement of gastrointestinal motility between each dose group by comparing the effectiveness and safety in patients undergoing colon resection.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2
Seoul, 138-736, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
comparison of different dosages of drug
Time frame: in hospitalization (Maximized 14 days)
Evaluation gastrointestinal function to the time of improvement gastrointestinal motility
LG Life Sciences
Industry
A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01613274
Colon Resection
Saint Paul, Minnesota, United States
View Trial DetailsNCT07386431
Bowel Endometriosis, Carcinogenesis
View Trial DetailsNCT07083076
Colon Resection
Manhasset, New York, United States
View Trial Details